

## CLAIMS

1. A combination comprising paroxetine or physiologically acceptable salts or solvates thereof and a therapeutically non-effective dose of 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)]-(2S-phenyl-piperidin-3S-yl)-amine or physiologically acceptable salts or solvates thereof.  
5
2. A combination as claimed in claim 1 comprising a therapeutically non-effective dose of paroxetine or physiologically acceptable salts or solvates thereof and a therapeutically non-effective dose of 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)]-(2S-phenyl-piperidin-3S-yl)-amine or physiologically acceptable salts or solvates thereof.  
10
3. A combination as claimed in claim 1 or claim 2 wherein the paroxetine is present as its hydrochloride hemihydrate salt and 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)]-(2S-phenyl-piperidin-3S-yl)-amine is present as its dihydrochloride salt.  
15
4. A combination as claimed in any claims 1 to 3 comprising paroxetine or physiologically salts or solvates thereof in an amount from 1 to 10 mg (measured as the free base).  
20
5. A combination as claimed in any claims 1 to 4 comprising paroxetine or physiologically salts or solvates thereof in an amount from 3.5 to 7.5 mg (measured as the free base).  
25
6. A combination as claimed in any claims 1 to 5 comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)]-(2S-phenyl-piperidin-3S-yl)-amine or physiologically salts or solvates thereof in an amount from 1 to 5 mg (measured as the free base).  
30
7. A combination as claimed in any claims 1 to 6 comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)]-(2S-phenyl-piperidin-3S-yl)-amine or physiologically salts or solvates thereof in an amount from 1 to 3 mg (measured as the free base).  
35

8. A combination as claimed in any claims 1 to 7 comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)]-(2S-phenyl-piperidin-3S-yl)-amine or physiologically salts or solvates thereof in an amount from 1 to 2.5 mg (measured as the free base).

5

9. A combination as claimed in any claims 1 to 8 comprising paroxetine or physiologically salts or solvates thereof in an amount from 1 to 10 mg (measured as the free base) and 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)]-(2S-phenyl-piperidin-3S-yl)-amine or physiologically salts or solvates thereof in an

10 amount from 1 to 5 mg (measured as the free base).

10. A combination as claimed in any claims 1 to 9 comprising paroxetine or physiologically salts or solvates thereof in an amount from 1 to 10 mg (measured as the free base) and 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)]-(2S-phenyl-piperidin-3S-yl)-amine or physiologically salts or solvates thereof in an

15 amount from 1 to 3 mg (measured as the free base).

11. A combination as claimed in any claims 1 to 10 comprising paroxetine or physiologically salts or solvates thereof in an amount from 1 to 10 mg (measured as the free base) and 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)]-(2S-phenyl-piperidin-3S-yl)-amine or physiologically salts or solvates thereof in an

20 amount from 1 to 2.5 mg (measured as the free base).

12. A combination as claimed in any claims 1 to 11 comprising paroxetine or physiologically salts or solvates thereof in an amount from 3.5 to 7.5 mg (measured as the free base) and 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)]-(2S-phenyl-piperidin-3S-yl)-amine or physiologically salts or solvates thereof in an amount from 1 to 5 mg (measured as the free base).

25

30 13. A combination as claimed in any claims 1 to 12 comprising paroxetine or physiologically salts or solvates thereof in an amount from 3.5 to 7.5 mg (measured as the free base) and 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)]-(2S-phenyl-piperidin-3S-yl)-amine or physiologically salts or solvates thereof in an amount from 1 to 3 mg (measured as the free base).

14. A combination as claimed in any claims 1 to 13 comprising paroxetine or physiologically salts or solvates thereof in an amount from 3.5 to 7.5 mg (measured as the free base) and 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenyl-piperidin-3S-yl)-amine or physiologically salts or solvates thereof in an amount from 1 to 2.5 mg (measured as the free base).

5

15. A combination according to any of claims 1 to 14 for use in the treatment and or prophylaxis of depression and /or anxiety.

10 16. A method for the treatment and/or prophylaxis of depression and/or anxiety in a mammal including a human, which comprises treating said animal with a therapeutically effective amount of a combination as claimed in any of claims 1 to 14.

15 17. A pharmaceutical formulation comprising a combination according to any of the claims 1 to 14 together with one or more pharmaceutically acceptable carriers or excipients.

20 18. The use of a combination according to any claims 1 to 14 in the manufacture of a therapeutically effective medicament for simultaneous or sequential administration for the treatment and/or prophylaxis of depression and /or anxiety.

25

30

35